Anhui Wanbang Pharmaceutical Technology Co.,Ltd. (SHE:301520)
China · Delayed Price · Currency is CNY 44.57
-0.45 (-1.00%)
At close: Feb 13, 2026
SHE:301520 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 287.81 | 371.69 | 317.16 | 246.21 | 200.44 | 133.09 |
Other Revenue | 7.41 | 7.41 | 24.65 | 14.57 | 10.65 | 6.04 |
| 295.21 | 379.09 | 341.81 | 260.78 | 211.09 | 139.13 | |
Revenue Growth (YoY) | -25.16% | 10.91% | 31.07% | 23.54% | 51.72% | 35.02% |
Cost of Revenue | 208.01 | 229.05 | 174.53 | 129.39 | 99.82 | 61.51 |
Gross Profit | 87.2 | 150.04 | 167.27 | 131.39 | 111.27 | 77.62 |
Selling, General & Admin | 31.92 | 31.77 | 25.21 | 16.97 | 15.37 | 11.88 |
Research & Development | 54.59 | 60.68 | 34.52 | 15.97 | 10.35 | 7.78 |
Other Operating Expenses | 0.35 | 0.36 | 0.51 | 0.16 | 0.82 | 0.92 |
Operating Expenses | 91.54 | 98.5 | 64.21 | 35.39 | 28.23 | 21.11 |
Operating Income | -4.33 | 51.54 | 103.06 | 95.99 | 83.04 | 56.51 |
Interest Expense | - | - | -0 | -0 | -0.01 | - |
Interest & Investment Income | 28.47 | 24.33 | 7.06 | 4.08 | 2.29 | 1.29 |
Other Non Operating Income (Expenses) | -2.78 | -0.16 | -0.16 | -0.01 | -0.06 | -0.01 |
EBT Excluding Unusual Items | 21.35 | 75.71 | 109.97 | 100.06 | 85.26 | 57.79 |
Gain (Loss) on Sale of Investments | 2.7 | 7.03 | 3.79 | - | - | - |
Gain (Loss) on Sale of Assets | - | 0.02 | - | - | - | - |
Asset Writedown | 0.26 | -0.04 | -0.02 | - | -0 | -0.07 |
Other Unusual Items | 11.52 | 6.77 | 5.91 | 11.09 | 9.07 | 5.04 |
Pretax Income | 35.83 | 89.5 | 119.64 | 111.15 | 94.33 | 62.75 |
Income Tax Expense | -5.02 | 3.97 | 11.55 | 12.41 | 12.46 | 8.24 |
Earnings From Continuing Operations | 40.84 | 85.53 | 108.09 | 98.73 | 81.87 | 54.52 |
Net Income | 40.84 | 85.53 | 108.09 | 98.73 | 81.87 | 54.52 |
Net Income to Common | 40.84 | 85.53 | 108.09 | 98.73 | 81.87 | 54.52 |
Net Income Growth | -62.38% | -20.87% | 9.48% | 20.60% | 50.18% | 104.94% |
Shares Outstanding (Basic) | 67 | 67 | 54 | 50 | 50 | 48 |
Shares Outstanding (Diluted) | 67 | 67 | 54 | 50 | 50 | 48 |
Shares Change (YoY) | 0.16% | 23.64% | 7.84% | 0.40% | 4.39% | 9.66% |
EPS (Basic) | 0.61 | 1.28 | 2.00 | 1.97 | 1.64 | 1.14 |
EPS (Diluted) | 0.61 | 1.28 | 2.00 | 1.97 | 1.64 | 1.14 |
EPS Growth | -62.44% | -36.00% | 1.52% | 20.12% | 43.86% | 86.89% |
Free Cash Flow | -11.18 | 5.02 | -14.05 | 21.63 | 39.84 | 40.24 |
Free Cash Flow Per Share | -0.17 | 0.07 | -0.26 | 0.43 | 0.80 | 0.84 |
Dividend Per Share | - | 0.350 | 0.500 | - | - | - |
Dividend Growth | - | -30.00% | - | - | - | - |
Gross Margin | 29.54% | 39.58% | 48.94% | 50.38% | 52.71% | 55.79% |
Operating Margin | -1.47% | 13.59% | 30.15% | 36.81% | 39.34% | 40.61% |
Profit Margin | 13.84% | 22.56% | 31.62% | 37.86% | 38.78% | 39.18% |
Free Cash Flow Margin | -3.79% | 1.32% | -4.11% | 8.29% | 18.87% | 28.93% |
EBITDA | 13.28 | 65.74 | 112.72 | 101.36 | 86.96 | 59.65 |
EBITDA Margin | 4.50% | 17.34% | 32.98% | 38.87% | 41.19% | 42.87% |
D&A For EBITDA | 17.62 | 14.21 | 9.66 | 5.37 | 3.92 | 3.14 |
EBIT | -4.33 | 51.54 | 103.06 | 95.99 | 83.04 | 56.51 |
EBIT Margin | -1.47% | 13.59% | 30.15% | 36.81% | 39.34% | 40.61% |
Effective Tax Rate | - | 4.43% | 9.66% | 11.17% | 13.21% | 13.13% |
Revenue as Reported | 295.21 | 379.09 | 341.81 | 260.78 | 211.09 | 139.13 |
Advertising Expenses | - | 0.56 | 0.91 | 1.62 | 1.65 | 1.06 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.